Biogen value drops by $18bn after Alzheimer’s drug failure 21-Mar-2019 By Ben Hargreaves Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimer’s – a key part of the former’s pipeline.
Alzheimer’s disease: Despite failures, hope for new treatment by 2025 04-Feb-2019 By Ben Hargreaves Despite Roche’s recent trial failure for crenezumab, the ProMIS team remain confident a disease-modifying treatment will be found in the next decade.
